EAST NORRITON, Pa., Sept. 19 Tengion Inc., a clinicalstage regenerative medicine company focused on the development of neo-organsand neo-tissues, today announced that it was one of only three companiesfeatured as models of venture capital-backed innovation and success at the35th Anniversary Celebration of the National Venture Capital Association(NVCA). P. Sherrill Neff, Partner at Quaker BioVentures -- a venture capitalinvestor in Tengion -- presented a Tengion case study at the event onThursday, September 18, 2008 in Mountain View, California.
For this 35th Anniversary Celebration event, the NVCA invited Tengion toshowcase its Autologous Organ Regeneration Platform(TM) for nearly 200invitation-only guests, including leading venture capitalists andentrepreneurs. The presentation was followed by a panel discussion of how tobest encourage technological advances and maintain a robust pipeline ofventure capital-backed innovation over the next 35 years.
"We are pleased and honored that the National Venture Capital Associationselected Tengion to present at this 35th Anniversary Celebration," said StevenNichtberger, M.D., President and CEO of Tengion. "We would like to extend ourthanks to Sherrill Neff and Brenda Gavin of Quaker BioVentures and all of ourinvestors who have worked so closely with the company to support our growthand the advances of our neo-organ and neo-tissue programs. We look forward tocontinuing to innovate and, ultimately, bringing important medical advances topatients who need them."
The NVCA represents more than 470 venture capital firms in the UnitedStates. Founded in 1973, the NVCA's mission is to foster a greaterunderstanding of the importance of venture capital to the U.S. economy, andsupport entrepreneurial activity and innovation. The organization has markedits 35th Anniversary with key news announcements and several events in 2008.
Tengion, a clinical stage biotechnology company, focuses on developing,manufacturing and commercializing human neo-organs and neo-tissues using ourAutologous Organ Regeneration Platform(TM). Tengion uses biocompatiblematerials and a patient's own (autologous) cells to create a functionalneo-organ or neo-tissue that is designed to catalyze the body's innate abilityto regenerate. Tengion's product candidates may ultimately address the mostcritical problems facing organ and tissue failure patients, enabling people tolead healthier lives without donor transplants or the side effects of relatedtherapies.
SOURCE Tengion Inc.